EUVIMEDEUVIMED entdecken
Crossref

Antimicrobial peptides under clinical investigation

Hye Been Koo, Jiwon Seo

Peptide Science · 2019-09 · 111 (5)

DOI: 10.1002/pep2.24122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Peptide Science, online erschienen am 03.06.2019. Verfasst von Hye Been Koo und 1 weiteren Autor:innen. Die Arbeit wurde bisher 366-mal zitiert (Crossref) und nennt 113 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overuse of conventional antibiotics as well as the slow pace of new antibiotic drug development leads to antimicrobial resistance (AMR). Because infections with multi‐drug resistant (MDR) pathogens have become a public health issue, the need for a novel class of antibiotics is urgent. Recently, antimicrobial peptides (AMPs) have emerged as a promising platform to fight against MDR bacteria ensuring broad‐spectrum antimicrobial activity and relatively low resistance emergence. Currently, a number of AMPs are undergoing clinical and preclinical trials against various infectious diseases. This review lists the 36 AMPs (27 clinical and 9 preclinical) with brief information about their origin, structure, mechanism, and development status. From the examples of AMPs under clinical investigation, we categorized several improvement strategies and highlighted directions for the future design of AMPs.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Koo, H. B., & Seo, J. (2019). Antimicrobial peptides under clinical investigation. Peptide Science, 111(5). https://doi.org/10.1002/pep2.24122

Vancouver

Koo HB, Seo J. Antimicrobial peptides under clinical investigation. Peptide Science. 2019;111(5). doi:10.1002/pep2.24122

BibTeX
@article{Koo2019,
  author = {Koo, Hye Been and Seo, Jiwon},
  title = {Antimicrobial peptides under clinical investigation},
  journal = {Peptide Science},
  year = {2019},
  volume = {111},
  number = {5},
  doi = {10.1002/pep2.24122}
}
Kostenlos starten →